About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

IRESSA™ (Gefitinib) in Breast Cancer Patients | Clinical Trials | Clareo Health

Back to clinical trial search

COMPLETEDPhase 2NCT00632723

IRESSA™ (Gefitinib) in Breast Cancer Patients

This is a phase II trial to assess whether IRESSA™ (gefitinib) has anti-tumour efficacy in patients with breast cancer. The trial proposes to enter 27 patients who have acquired resistance to tamoxife...

Lead sponsor: AstraZeneca•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

AstraZeneca

Age

18 - No limit years

Sex

FEMALE

Healthy Volunteers

No

Inclusion Criteria

•histological or cytological confirmation of breast cancer that is either
•* a primary tumour in a patient unfit for or who has declined surgery
•* advanced (locally or metastatic) disease
•acquired resistance to tamoxifen or ER negative tumour
•at least one measurable or assessable lesion
•WHO performance status 0 - 2
•life expectancy of 12 weeks or more

Exclusion Criteria

•more than one previous chemotherapy regimens for advanced disease
•prior anthracycline chemotherapy (\> 250 mg/m2 adriamycin)
•radiotherapy completed within 14 days prior to Day 1 of treatment
•incomplete healing from prior oncologic or other major surgery
•signs of neurological symptoms consistent with spinal cord compression
•any evidence of clinically active interstitial lung disease (patients with chronic stable

Related studies

RECRUITINGPhase 1

Study of Autologous CAR-T Cells Targeting B7-H3 in TNBC iC9-CAR.B7-H3 T Cells

NCT06347068 · Breast Cancer, Relapse, and more

RECRUITINGPhase 3

Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial

NCT06500481 · Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, and more

A Mixed-Methods Metabolomics Investigation of Lifestyle and Energy Balance During Breast Cancer Survivorship

NCT07655934 · Breast Cancer

RECRUITINGPhase 1/2

A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors

NCT06188520 · ER+ HER2- Advanced Breast Cancer, High-grade Serous Ovarian Cancer (HGSOC)

Culturally Adapting an Intervention to Increase Genetic Testing in African American Cancer Survivors

NCT07436078 · Female Breast Cancer, Prostate Cancer, and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: April 22, 2009Terms

Trial snapshot

StatusCOMPLETED

PhasePHASE2

Enrollment54

Start dateApr 2001

Last updatedApr 22, 2009

Condition

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 22, 2009Data synced to Clareo: June 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions